drugset / Trial / NCT00193583

Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors

NCT00193583

Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this phase I study we will characterize the safety, tolerability, maximum tolerated dose and dose-limiting toxicity of weekly bolus topotecan when administered in combination with two different dosing schedules of carboplatin. We will also evaluate any antitumor activity of these combination regimens.

Timeline

Start
2003-05
Primary completion
2004-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject Topotecan Small molecule

Indications